A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP

Clinical trial NCT05020288 · UNKNOWN

Trial details

NCT number: NCT05020288
Sponsor: Shandong University
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

Immune Thrombocytopenia Bruton's Tyrosine Kinase

Start date: 2021-09-01
Primary completion: 2023-12-31
Enrollment: 40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.